Oppenheimer analyst Jay Olson maintained a Buy rating on TherapeuticsMD (TXMD) today. The company’s shares opened today at $5.54.
According to TipRanks.com, Olson has 0 stars on 0-5 star ranking scale with an average return of -2.6% and a 45.0% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Spero Therapeutics Inc.
Currently, the analyst consensus on TherapeuticsMD is a Moderate Buy with an average price target of $27, a 387.4% upside from current levels. In a report issued on March 12, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $27 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.66 and a one-year low of $3.51. Currently, TherapeuticsMD has an average volume of 3.19M.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Read More on TXMD:
